These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 33522314

  • 1. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M, Storey PP, Levin HJ, Obeid A, Patel SN, Kuley B, Hsu J, Spirn MJ, Fineman M, Klufas MA, Gupta O, Ho AC, Garg SJ.
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [Abstract] [Full Text] [Related]

  • 2. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC, Yu Y, VanderBeek BL.
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC, Fight Retinal Blindness! Study Group.
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [Abstract] [Full Text] [Related]

  • 5. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K, Chin EK, Bennett SR, Williams DF, Ryan EH, Dev S, Mittra RA, Quiram PA, Davies JB, Parke DW, Johnson JB, Cantrill HL, Almeida DRP.
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS, Rao P, Lee IJ, Woodward MA, Faia LJ, Wolfe JD, Capone A, Covert D, Dass AB, Drenser KA, Garretson BR, Hassan TS, Margherio A, Oh KT, Raephaelian PV, Randhawa S, Sneed S, Trese MT, Yedavally S, Williams GA, Ruby AJ.
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [Abstract] [Full Text] [Related]

  • 9. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S, Alsulaiman SM, Alrushood AA, Almasaud J, Arevalo JF.
    Middle East Afr J Ophthalmol; 2016 Jan; 23(1):60-3. PubMed ID: 26957840
    [Abstract] [Full Text] [Related]

  • 10. Bilateral endophthalmitis following bilateral same-day anti-VEGF injections.
    Sepetis AE, Clarke B, Gupta B.
    Acta Ophthalmol; 2021 Feb; 99(1):e131-e133. PubMed ID: 32533656
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F, Albiani DA, Kirker AW, Merkur AB.
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [Abstract] [Full Text] [Related]

  • 12. The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Writing committee for the Post-Injection Endophthalmitis Study Group, Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, Shah SP, Chen E, Abbey A, Ferrone PJ, Shah CP, Liang MC, Stem MS, Ali Khan M, Yonekawa Y, Garg SJ.
    Ophthalmology; 2021 Nov; 128(11):1620-1626. PubMed ID: 34019955
    [Abstract] [Full Text] [Related]

  • 13. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA, Knickelbein JE, Doft BH, Balasubramani GK, Wisniewski S.
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y, Tan CS.
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y, Matsushima H, Kinoshita S, Senoo T, Tochikubo T, Kadonosono K.
    Ophthalmologica; 2011 Apr; 226(3):145-50. PubMed ID: 21811052
    [Abstract] [Full Text] [Related]

  • 19. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M.
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.